doi: 10.1021/jm00018a002.
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)
Affiliations
- PMID: 7658429
- DOI: 10.1021/jm00018a002
Item in Clipboard
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)
J Med Chem.
.
No abstract available
Similar articles
-
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.J Pharmacol Exp Ther. 1996 Jan;276(1):150-60. J Pharmacol Exp Ther. 1996. PMID: 8558425
-
Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90. doi: 10.1016/s0014-2999(96)00718-2. Eur J Pharmacol. 1996. PMID: 8997599
-
Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.Behav Pharmacol. 2004 Feb;15(1):85-9. doi: 10.1097/00008877-200402000-00010. Behav Pharmacol. 2004. PMID: 15075630
-
Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.CNS Drug Rev. 2001 Fall;7(3):305-16. doi: 10.1111/j.1527-3458.2001.tb00201.x. CNS Drug Rev. 2001. PMID: 11607045 Free PMC article. Review.
-
Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.J Neural Transm (Vienna). 1997;104(4-5):341-62. doi: 10.1007/BF01277656. J Neural Transm (Vienna). 1997. PMID: 9295170 Review.
Cited by
-
The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413.Int J Med Chem. 2011;2011:424535. doi: 10.1155/2011/424535. Epub 2011 Mar 24. Int J Med Chem. 2011. PMID: 25954518 Free PMC article. Review.
-
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Biol Psychiatry. 2017. PMID: 26946382 Free PMC article. Review.
-
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.Br J Pharmacol. 2000 Apr;129(7):1355-64. doi: 10.1038/sj.bjp.0703189. Br J Pharmacol. 2000. PMID: 10742291 Free PMC article.
-
Antiparkinson prodrugs.Molecules. 2008 Jan 16;13(1):46-68. doi: 10.3390/molecules13010046. Molecules. 2008. PMID: 18259129 Free PMC article. Review.
-
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.J Parkinsons Dis. 2020;10(4):1515-1527. doi: 10.3233/JPD-202188. J Parkinsons Dis. 2020. PMID: 32986682 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Chemical Information